CA2095539A1 - Diagnostic et traitement de la sclerose en plaques - Google Patents
Diagnostic et traitement de la sclerose en plaquesInfo
- Publication number
- CA2095539A1 CA2095539A1 CA002095539A CA2095539A CA2095539A1 CA 2095539 A1 CA2095539 A1 CA 2095539A1 CA 002095539 A CA002095539 A CA 002095539A CA 2095539 A CA2095539 A CA 2095539A CA 2095539 A1 CA2095539 A1 CA 2095539A1
- Authority
- CA
- Canada
- Prior art keywords
- msv
- antibody
- antigen
- antigenic fragment
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract 12
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 claims abstract description 27
- 241000700605 Viruses Species 0.000 claims abstract description 8
- 230000028993 immune response Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract 7
- 238000001514 detection method Methods 0.000 claims abstract 4
- 210000005013 brain tissue Anatomy 0.000 claims abstract 3
- 241000712045 Morbillivirus Species 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 241000282326 Felis catus Species 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 210000004754 hybrid cell Anatomy 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 12
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 235000011330 Armoracia rusticana Nutrition 0.000 claims 1
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- 238000012760 immunocytochemical staining Methods 0.000 claims 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000000405 serological effect Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 8
- 201000005505 Measles Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003967 CLP Anatomy 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 101150038575 clpS gene Proteins 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 description 1
- PCDTWCMMSBQBDL-SFQUDFHCSA-N (3e)-3-(5-hydroxy-5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-ylidene)-n,n-dimethylpropan-1-amine oxide Chemical compound C1C(O)C2=CC=CC=C2C(=C/CC[N+](C)([O-])C)/C2=CC=CC=C21 PCDTWCMMSBQBDL-SFQUDFHCSA-N 0.000 description 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
- FWVCSXWHVOOTFJ-UHFFFAOYSA-N 1-(2-chloroethylsulfanyl)-2-[2-(2-chloroethylsulfanyl)ethoxy]ethane Chemical compound ClCCSCCOCCSCCCl FWVCSXWHVOOTFJ-UHFFFAOYSA-N 0.000 description 1
- 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101000880640 Centruroides elegans Beta-mammal toxin CeII9 Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 101150073597 DLST gene Proteins 0.000 description 1
- 101100295675 Dictyostelium discoideum odhB gene Proteins 0.000 description 1
- 101100536931 Escherichia coli (strain K12) thiD gene Proteins 0.000 description 1
- 101100159279 Escherichia coli (strain K12) yajL gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000657326 Homo sapiens Protein TANC2 Proteins 0.000 description 1
- 241000531897 Loma Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001163743 Perlodes Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100034784 Protein TANC2 Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 208000006257 Rinderpest Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 101150018104 tlcC gene Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPK3352 | 1990-11-14 | ||
| AUPK335290 | 1990-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2095539A1 true CA2095539A1 (fr) | 1992-05-15 |
Family
ID=3775068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002095539A Abandoned CA2095539A1 (fr) | 1990-11-14 | 1991-11-14 | Diagnostic et traitement de la sclerose en plaques |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0557388A4 (fr) |
| JP (1) | JP3266612B2 (fr) |
| AU (1) | AU646522B2 (fr) |
| CA (1) | CA2095539A1 (fr) |
| WO (1) | WO1992008785A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173091D0 (da) * | 1991-10-11 | 1991-10-11 | Schleroseforeningen The Danish | Biologisk materiale |
| GB9310657D0 (en) * | 1993-05-24 | 1993-07-07 | Univ London | Retrovirus |
| EP1068361A1 (fr) * | 1998-04-08 | 2001-01-17 | MS Research A/S | Diagnostic de la sclerose en plaques et d'autres maladies demyelinisantes |
| BR0112969A (pt) | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composições contendo-as |
| WO2004030522A2 (fr) | 2002-10-02 | 2004-04-15 | Dmi Biosciences, Inc. | Diagnostic et controle de maladies |
| KR20120091266A (ko) | 2003-05-15 | 2012-08-17 | 디엠아이 바이오사이언시스, 인크 | Ｔ-세포 매개성 질환의 치료 방법 |
| EP2300011A4 (fr) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | Procédés et composés thérapeutiques |
| WO2012033792A2 (fr) | 2010-09-07 | 2012-03-15 | Dmi Acquisition Corp. | Traitement de maladies |
| JP6203734B2 (ja) | 2011-10-10 | 2017-09-27 | アンピオ ファーマシューティカルズ，インコーポレイテッド | 変形性関節疾患の治療 |
| BR112014007657A2 (pt) | 2011-10-10 | 2017-04-11 | Ampio Pharmaceuticals Inc | dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação |
| EA201490737A1 (ru) | 2011-10-28 | 2014-09-30 | Ампио Фармасьютикалз, Инк. | Лечение ринита |
| WO2014145729A2 (fr) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions pour la mobilisation, l'écotropisme, l'expansion et la différenciation de cellules souches et leurs méthodes d'utilisation |
| RU2020136589A (ru) | 2014-08-18 | 2020-12-24 | Ампио Фармасьютикалз, Инк. | Лечение дегенеративных заболеваний суставов |
| WO2016209969A1 (fr) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ218050A (en) * | 1985-11-13 | 1989-05-29 | Wistar Inst | Test for the presence of htlv-1v |
| EP0326395A2 (fr) * | 1988-01-29 | 1989-08-02 | City Of Hope | Méthode de détection et d'identification de certaines séquences virales |
-
1991
- 1991-11-14 CA CA002095539A patent/CA2095539A1/fr not_active Abandoned
- 1991-11-14 EP EP19910920470 patent/EP0557388A4/en not_active Withdrawn
- 1991-11-14 WO PCT/AU1991/000519 patent/WO1992008785A1/fr not_active Application Discontinuation
- 1991-11-14 JP JP50018192A patent/JP3266612B2/ja not_active Expired - Fee Related
- 1991-11-14 AU AU89555/91A patent/AU646522B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU8955591A (en) | 1992-06-11 |
| JP3266612B2 (ja) | 2002-03-18 |
| EP0557388A4 (en) | 1994-07-06 |
| JPH06502764A (ja) | 1994-03-31 |
| EP0557388A1 (fr) | 1993-09-01 |
| WO1992008785A1 (fr) | 1992-05-29 |
| AU646522B2 (en) | 1994-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2095539A1 (fr) | Diagnostic et traitement de la sclerose en plaques | |
| Baron et al. | Evidence for a high and specific concentration of (Na+, K+) ATPase in the plasma membrane of the osteoclast | |
| Tischer et al. | A very small porcine virus with circular single-stranded DNA | |
| Austin et al. | Evidence of ortho-and paramyxoviruses in fauna from Antarctica | |
| Eash et al. | The human polyomaviruses | |
| Hassan et al. | Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry | |
| Bhattacharya et al. | Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress | |
| Jackson et al. | Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses | |
| CN106619515A (zh) | 脂质体组合物及其用途 | |
| Poruchynsky et al. | Rotavirus protein rearrangements in purified membrane-enveloped intermediate particles | |
| ES2524975T3 (es) | Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células | |
| JP2004520841A (ja) | 細胞培養物からウイルスを抽出する方法 | |
| Holt et al. | Epidermal growth factor induced tyrosine phosphorylation of nuclear proteins associated with translocation of epidermal growth factor receptor into the nucleus | |
| JP6772155B2 (ja) | エンテロウイルス７１動物モデル | |
| Husain et al. | Evidence against an essential role of COPII-mediated cargo transport to the endoplasmic reticulum-Golgi intermediate compartment in the formation of the primary membrane of vaccinia virus | |
| Johnson et al. | Experimental subacute sclerosing panencephalitis: selective disappearance of measles virus matrix protein from the central nervous system | |
| ZA200700323B (en) | Recombinant rabies virus compositions | |
| Maldonado et al. | Group-specific antigen shared by the members of the reticuloendotheliosis virus complex | |
| Gibbons et al. | Rotavirus NSP4: cell type-dependent transport kinetics to the exofacial plasma membrane and release from intact infected cells | |
| Murti et al. | Interaction of frog virus 3 with the cytoskeleton | |
| Daniel et al. | Herpes virus aotus: a latent herpesvirus from owl monkeys (Aotus trivirgatus) isolation and characterization | |
| Fujimoto et al. | Immunocytochemical localization of fodrin and ankyrin in bovine chromaffin cells in vitro. | |
| CN107982526A (zh) | 一种多跨膜区蛋白抗体的筛选方法及其应用 | |
| JP4785531B2 (ja) | マーカーワクチンとしてのニューカッスル病ウイルスのエスケープミュータント | |
| Ausseil et al. | Dinoflagellate centrosome: associated proteins old and new |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |